Breast cancer cells induce osteolytic bone lesions in vivo through a reduction in osteoblast activity in mice.

Bone metastases are severely debilitating and have a significant impact on the quality of life of women with metastatic breast cancer. Treatment options are limited and in order to develop more targeted therapies, improved understanding of the complex mechanisms that lead to bone lesion development...

Full description

Bibliographic Details
Main Authors: Laura S Gregory, Wilson Choi, Leslie Burke, Judith A Clements
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3772030?pdf=render
_version_ 1819237745228251136
author Laura S Gregory
Wilson Choi
Leslie Burke
Judith A Clements
author_facet Laura S Gregory
Wilson Choi
Leslie Burke
Judith A Clements
author_sort Laura S Gregory
collection DOAJ
description Bone metastases are severely debilitating and have a significant impact on the quality of life of women with metastatic breast cancer. Treatment options are limited and in order to develop more targeted therapies, improved understanding of the complex mechanisms that lead to bone lesion development are warranted. Interestingly, whilst prostate-derived bone metastases are characterised by mixed or osteoblastic lesions, breast-derived bone metastases are characterised by osteolytic lesions, suggesting unique regulatory patterns. This study aimed to measure the changes in bone formation and bone resorption activity at two time-points (18 and 36 days) during development of the bone lesion following intratibial injection of MDA-MB-231 human breast cancer cells into the left tibiae of Severely Combined Immuno-Deficient (SCID) mice. The contralateral tibia was used as a control. Tibiae were extracted and processed for undecalcified histomorphometric analysis. We provide evidence that the early bone loss observed following exposure to MDA-MB-231 cells was due to a significant reduction in mineral apposition rate, rather than increased levels of bone resorption. This suggests that osteoblast activity was impaired in the presence of breast cancer cells, contrary to previous reports of osteoclast-dependent bone loss. Furthermore mRNA expression of Dickkopf Homolog 1 (DKK-1) and Noggin were confirmed in the MDA-MB-231 cell line, both of which antagonise osteoblast regulatory pathways. The observed bone loss following injection of cancer cells was due to an overall thinning of the trabecular bone struts rather than perforation of the bone tissue matrix (as measured by trabecular width and trabecular separation, respectively), suggesting an opportunity to reverse the cancer-induced bone changes. These novel insights into the mechanisms through which osteolytic bone lesions develop may be important in the development of new treatment strategies for metastatic breast cancer patients.
first_indexed 2024-12-23T13:25:13Z
format Article
id doaj.art-d729da9d31a340a7a47666a520fdc9d6
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-23T13:25:13Z
publishDate 2013-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-d729da9d31a340a7a47666a520fdc9d62022-12-21T17:45:19ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0189e6810310.1371/journal.pone.0068103Breast cancer cells induce osteolytic bone lesions in vivo through a reduction in osteoblast activity in mice.Laura S GregoryWilson ChoiLeslie BurkeJudith A ClementsBone metastases are severely debilitating and have a significant impact on the quality of life of women with metastatic breast cancer. Treatment options are limited and in order to develop more targeted therapies, improved understanding of the complex mechanisms that lead to bone lesion development are warranted. Interestingly, whilst prostate-derived bone metastases are characterised by mixed or osteoblastic lesions, breast-derived bone metastases are characterised by osteolytic lesions, suggesting unique regulatory patterns. This study aimed to measure the changes in bone formation and bone resorption activity at two time-points (18 and 36 days) during development of the bone lesion following intratibial injection of MDA-MB-231 human breast cancer cells into the left tibiae of Severely Combined Immuno-Deficient (SCID) mice. The contralateral tibia was used as a control. Tibiae were extracted and processed for undecalcified histomorphometric analysis. We provide evidence that the early bone loss observed following exposure to MDA-MB-231 cells was due to a significant reduction in mineral apposition rate, rather than increased levels of bone resorption. This suggests that osteoblast activity was impaired in the presence of breast cancer cells, contrary to previous reports of osteoclast-dependent bone loss. Furthermore mRNA expression of Dickkopf Homolog 1 (DKK-1) and Noggin were confirmed in the MDA-MB-231 cell line, both of which antagonise osteoblast regulatory pathways. The observed bone loss following injection of cancer cells was due to an overall thinning of the trabecular bone struts rather than perforation of the bone tissue matrix (as measured by trabecular width and trabecular separation, respectively), suggesting an opportunity to reverse the cancer-induced bone changes. These novel insights into the mechanisms through which osteolytic bone lesions develop may be important in the development of new treatment strategies for metastatic breast cancer patients.http://europepmc.org/articles/PMC3772030?pdf=render
spellingShingle Laura S Gregory
Wilson Choi
Leslie Burke
Judith A Clements
Breast cancer cells induce osteolytic bone lesions in vivo through a reduction in osteoblast activity in mice.
PLoS ONE
title Breast cancer cells induce osteolytic bone lesions in vivo through a reduction in osteoblast activity in mice.
title_full Breast cancer cells induce osteolytic bone lesions in vivo through a reduction in osteoblast activity in mice.
title_fullStr Breast cancer cells induce osteolytic bone lesions in vivo through a reduction in osteoblast activity in mice.
title_full_unstemmed Breast cancer cells induce osteolytic bone lesions in vivo through a reduction in osteoblast activity in mice.
title_short Breast cancer cells induce osteolytic bone lesions in vivo through a reduction in osteoblast activity in mice.
title_sort breast cancer cells induce osteolytic bone lesions in vivo through a reduction in osteoblast activity in mice
url http://europepmc.org/articles/PMC3772030?pdf=render
work_keys_str_mv AT laurasgregory breastcancercellsinduceosteolyticbonelesionsinvivothroughareductioninosteoblastactivityinmice
AT wilsonchoi breastcancercellsinduceosteolyticbonelesionsinvivothroughareductioninosteoblastactivityinmice
AT leslieburke breastcancercellsinduceosteolyticbonelesionsinvivothroughareductioninosteoblastactivityinmice
AT judithaclements breastcancercellsinduceosteolyticbonelesionsinvivothroughareductioninosteoblastactivityinmice